The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. DS3610 is an investigational STING agonist ...
CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback